Axovant Plans Nelotanserin PhIII But Trial Endpoint Has Eyebrows Raised
Axovant will move its 5HT2A receptor, nelotanserin, into Phase III studies later this year for Lewy body dementia patients, but the company is switching gears to focus on motor function over its previously stated target of visual hallucinations in patients.
You may also be interested in...
Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure
Axovant's stock fell 74% based on intepirdine's Phase III failure, but parent company Roivant recently raised $1.1bn, showing that investors were willing to fund more new Vants regardless of the risky study's outcome.
Ovid Therapeutics: Seeking Innovation In Epilepsy Treatment
Rising Leader Julia Tsai wants to see Ovid Therapeutics become a market leading epilepsy company that listens to the needs of patients and develops innovative drugs to treat a spectrum of epileptic indications and symptoms.
Synaffix’s Serial Dealmaker On ADC Platform Success And Expanding Into Gene Therapy
Anthony DeBoer, head of business development at Synaffix, joined the company in 2014 and has helped develop a platform technology business model in the antibody drug conjugate space, where Synaffix has become one of the leading technology providers enabling best-in-class therapeutic candidates.